Real-world clinical outcome of sacituzumab govitecan (SG) in HER2-negative metastatic breast cancer. Assessing venous thromboembolism risk in HR+/HER2- breast cancer patients receiving CDK4/6 ...

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

Persistent outcome disparities, particularly worse prognoses for Black women with breast cancer, persist even within the same genomic risk categories. Effective management requires integrating genomic ...

The Stagljar Lab is a global leader in proteomics and chemical genomics, specializing in unraveling protein-protein interactions of human membrane proteins. Pivotal in cancer and rare genetic diseases ...

Please provide your email address to receive an email when new articles are posted on . The CNSide assay aims to help clinicians with early diagnosis, treatment plans for those with CNS cancers. The ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...

Assays to measure homologous recombination deficiency (HRD) in ovarian cancer vary widely, underscoring the need for standardization, since inconsistent assay results can influence treatment decisions ...

Shares of Tempus AI, Inc. (TEM) jumped 17% on Monday morning after the company announced a new liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in ...

DELRAY BEACH, Fla.--(BUSINESS WIRE)--PanGIA Biotech–a pioneer in liquid biopsy technology–today announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics ...